Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial dysfunction in lung ageing and disease.

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

COPD 2020: new directions needed.

American journal of physiology. Lung cellular and molecular physiology·2020
Same author

Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.

The Lancet. Respiratory medicine·2020
Same author

Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model.

Journal of immunology (Baltimore, Md. : 1950)·2020
Same author

Sex and gender: modifiers of health, disease, and medicine.

Lancet (London, England)·2020
Same author

Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach.

Journal of clinical medicine·2020

Related Experiment Video

Updated: Jun 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

New drugs for asthma.

Peter J Barnes1

  • 1National Heart and Lung Institute, Imperial College, London, United Kingdom.

Discovery Medicine
|August 14, 2010
PubMed
Summary

Asthma, a chronic inflammatory airway disease, is increasingly managed with inhaled corticosteroids and long-acting beta2-agonists. This combination therapy improves asthma control, reduces hospitalizations, and lowers mortality rates.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Asthma is a prevalent chronic respiratory disease globally, with increasing prevalence in developing nations.
  • Historically viewed as bronchoconstriction, asthma is now recognized as an inflammatory airway disease.
  • Key inflammatory markers include mast cell activation, eosinophil infiltration, and T helper 2 (Th2) lymphocyte activity.

Purpose of the Study:

  • To highlight the shift in asthma management paradigms.
  • To emphasize the role of anti-inflammatory treatments in modern asthma care.
  • To discuss the efficacy of current combination therapies.

Main Methods:

  • Review of current understanding of asthma pathophysiology.
  • Analysis of the impact of inhaled corticosteroids on asthma management.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

  • Evaluation of combination therapies including corticosteroids and long-acting beta2-agonists.

    • Main Results:

    • Inhaled corticosteroids have significantly improved asthma control, reduced hospital admissions, and decreased mortality.
    • Combination inhalers of corticosteroids and long-acting beta2-agonists (salmeterol, formoterol) represent the most effective current therapy.
    • These combination therapies are increasingly utilized for persistent asthma symptoms.

    Conclusions:

    • Modern asthma management has transitioned to an anti-inflammatory approach, primarily using inhaled corticosteroids.
    • Combination therapy with inhaled corticosteroids and long-acting beta2-agonists offers superior efficacy for persistent asthma.
    • This therapeutic strategy has revolutionized patient outcomes, improving quality of life and reducing disease burden.